TABLE 7.
Susceptibilities of lersivirine-resistant HIV-1 isolates to lersivirine, efavirenz, and etravirinea
| Virus backboneb | Experimental condition | RT mutation(s) | Fold change in EC50 from that for wt virus of indicated drugc |
||
|---|---|---|---|---|---|
| Lersivirine | EFV | ETV | |||
| wt | Virus after passage through lersivirine | V108I | 5.5 | 1.5 | 0.9 |
| K103N | Input virus | K103N | 2.7 | 35.5 | 1.4 |
| Virus after passage through lersivirine | K103N, V108V/I | 5.0 | 54.8 | 1.1 | |
| Y181C | Input virus | Y181C | 1.8 | 1.9 | 4.4 |
| Virus after passage through lersivirine | Y181C, V179V/D | 11.1 | 9.5 | 13.0 | |
| Virus after passage through lersivirine | Y181C, V108V/I, V179V/D | 8.0 | 7.2 | 9.4 | |
a
Mutations were identified in the GeneSeq HIV assay at Monogram Biosciences. Susceptibilities to lersivirine, efavirenz (EFV), and etravirine (ETV) were determined in Monogram Biosciences's PhenoSense assay.
b
Serial passage of wt virus or K103N or Y181C site-directed mutants in fixed concentrations of lersivirine. The wt and K103N and Y181C mutant viruses were passaged at 17 days, 10 days, and 17 days, respectively.
c
The drug-sensitive virus CNDO was used as the reference virus for estimation of fold change in EC50 in the PhenoSense assay; this value was then used to determine the EC50 fold change from that for the wt virus.